Gyre Therapeutics (GYRE) Misses Q2 EPS by 6c

Gyre Therapeutics (NASDAQ: GYRE) reported Q2 EPS of ($0.12), $0.06 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $29.1 million versus the consensus estimate of $26.49 million.

For earnings history and earnings-related data on Gyre Therapeutics (GYRE) click here.

You May Also Be Interested In

• Apple alleges defendant in trade secret case against OpenAI accessed power converter circuit schematic while at OpenAI - legal filing
• Invesco names Marty Franc to lead Asia Pacific as Andrew Lo retires
• Frontier Airlines to return 13 aircraft early, lease 10 new jets